By vgreene, 30 October, 2020 No statistical difference in clinical worsening w in 14 days TCZ 28 3 vs SOC 27 RR 1 05 95 CI 0 59 1 86
By vgreene, 30 October, 2020 Prospective open label randomized study 126 hospitalized pts median age 60y w COVID 19 pneumonia received TCZ 8 mg kg max 800 mg w in 8h of randomization w 2nd dose 12h later n 60 or SOC only n 66
By vgreene, 30 October, 2020 Study considerations randomized but open label small sample size study interrupted due to low enrollment excluded pts at risk for ICU admission significant imbalances btwn groups incl antiviral use and baseline labs
By vgreene, 30 October, 2020 Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID 19 Pneumonia A Randomized Clinical Trial
By vgreene, 30 October, 2020 TCZ had lower risk of death vs no TCZ HR 0 71 95 0 56 0 92 30 day mortality TCZ 27 5 vs 37 1 risk difference 9 6 95 CI 3 1 16
By vgreene, 30 October, 2020 Multicenter cohort study 3 924 hospitalized pts median age 62y received TCZ w in 2 days of ICU admission n 433 vs no TCZ TCZ pts were younger w higher prevalence of hypoxemia on ICU admission and more likely to receive CS
By vgreene, 30 October, 2020 Study considerations non randomized inverse probability weighting significant imbalances btwn groups number of TCZ doses not recorded CS duration not recorded missing data for some key variables
